Kodiak Sciences (KOD) Reports Q4 EPS of ($1.05)
Kodiak Sciences Inc. (NASDAQ:KOD),
8 Healthcare Stocks Insiders Are Buying. Kodiak Sciences Inc. on April 1, 2026. (NASDAQ:KOD) reported Q4 EPS of ($1.05), compared to (84c) last year. Chief Executive Officer Victor Perlroth said momentum was building, citing “positive Phase 3 results” from the GLOW2 study and progress on late-stage and pipeline programs that support the company’s long-term strategy.
On March 27, 2026, UBS, Kodiak Sciences Inc. (NASDAQ:KOD) raised its price target to $80 from the previous $50 and maintained a Buy rating on the shares. UBS said both tarcocimab VEGF and IL6 are on the rise.
Photo by José Antonio Otegui Auzmendi from Pexels
Similarly, HC Jefferies raised its price target on Kodiak Sciences Inc. (NASDAQ:KOD) to $56 from the previous $39 and maintained a Buy rating on the shares; He noted that GLOW2 results showed improved safety and efficacy compared to GLOW1, with the reformulation viewed as a safety improvement and potential durability driver in the Phase III DAYbreak study, as well as supporting the earlier Biologics License Application timing.
Kodiak Sciences Inc. (NASDAQ:KOD) develops treatments for retinal diseases.
While we recognize KOD’s potential as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for a deeply undervalued AI stock that could also benefit significantly from the Trump-era tariffs and support trend, check out our free report. Best short term AI stocks.
READ NEXT: 33 Stocks That Should Double in 3 Years And Cathie Wood 2026 Portfolio: The 10 Best Stocks to Buy.
Description: None. Follow Insider Monkey on Google News.
